Back to top

gene-editing: Archive

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXPositive Net Change PBYIPositive Net Change ADMAPositive Net Change CRSPPositive Net Change

Zacks Equity Research

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

RHHBYPositive Net Change SRPTPositive Net Change ADMAPositive Net Change IMCRNegative Net Change

Zacks Equity Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

PBYIPositive Net Change ADMAPositive Net Change ACADPositive Net Change SANANegative Net Change

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

RHHBYPositive Net Change SRPTPositive Net Change PBYIPositive Net Change SLDBNegative Net Change